Hi,
If you have been on our website recently you have already met Dr. Nabhan talking about patient reported outcomes. This time at ASH 2018, we also discussed his innovative research using claims data from 2014- 2017 on the total cost of care for CLL patients who took ibrutinib versus chemotherapy or chemo-immunotherapy (CT/CIT).
Guess what- The total cost is cheaper with ibrutinib.
But here is the really scary and depressing part.
1,464 patients received chemotherapy alone. This is a huge concern as there is no role for chemotherapy on its own in CLL. In fact, there is very little role for chemo-immunotherapy.
The trial was designed to look at the economic impact of drug choice, but to his credit Dr. Nabhan highlights his finding about the lousy treatment too many patients are still getting.
Here is the link my ASH 2018 interview: cllsociety.org/2019/08/ash-...
I have more coming from Dr. Nabhan from ASH soon. I like doing stuff that isn’t just the science research but the real world data
Stay strong.
We are all in this together.
Brian
Brian Koffman MDCM DCFP, DABFM, MS Ed
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc